XL184 (cabozantinib) for medullary thyroid carcinoma

被引：35

作者：

Durante, Cosimo ^{[1
]}

Russo, Diego ^{[2
]}

Verrienti, Antonella ^{[1
]}

Filetti, Sebastiano ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Internal Med & Clin Special, I-00161 Rome, Italy

[2] Univ Catanzaro Magna Graecia, Dept Pharmacobiol Sci, I-88100 Catanzaro, Italy

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期

关键词：

medullary thyroid carcinoma; MET; RET; targeted therapy; tyrosine kinase inhibitors; VEGFRs; PHASE-II; RET; CANCER; MET; THERAPY; GROWTH; ACTIVATION; RESISTANCE; MUTATIONS; PROGNOSIS;

D O I：

10.1517/13543784.2011.559163

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: We review preliminary data on the safety and efficacy of XL184 in metastatic MTC based on an extensive search of the literature, which included published articles, abstracts and website information. In particular, the review focuses on the rationale for using XL184 in advanced MTC. The compound has been specifically designed to target multiple signaling pathways, and this is expected to produce synergistic antitumor effects superior to those achieved by single-kinase inhibition. Preliminary results from the Phase I study of XL184 seem to support this hypothesis. Expert opinion: Multiple receptor tyrosine kinases (RTKs) are concomitantly activated in the same tumor. The blockade of a single RTK may engage compensatory signaling that maintains cell growth. Targeting multiple kinases might overcome both intrinsic and acquired resistance to antitumoral drugs.

引用

页码：407 / 413

页数：7

共 41 条

[1] Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis [J].

Bardelli, A ;

Basile, ML ;

Audero, E ;

Giordano, S ;

Wennström, S ;

Ménard, S ;

Comoglio, PM ;

Ponzetto, C .

ONCOGENE, 1999, 18 (05) :1139-1146

[2] Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors [J].

Carlomagno, F ;

Guida, T ;

Anaganti, S ;

Vecchio, G ;

Fusco, A ;

Ryan, AJ ;

Billaud, M ;

Santoro, M .

ONCOGENE, 2004, 23 (36) :6056-6063

[3] A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization [J].

Castellone, Maria D. ;

Verrienti, Antonella ;

Rao, Deva Magendra ;

Sponziello, Marialuisa ;

Fabbro, Dora ;

Muthu, Magesh ;

Durante, Cosimo ;

Maranghi, Marianna ;

Damante, Giuseppe ;

Pizzolitto, Stefano ;

Costante, Giuseppe ;

Russo, Diego ;

Santoro, Massimo ;

Filetti, Sebastiano .

CLINICAL ENDOCRINOLOGY, 2010, 73 (04) :529-534

[4] Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma [J].

Chiefari, E ;

Russo, D ;

Giuffrida, D ;

Zampa, GA ;

Meringolo, D ;

Arturi, F ;

Chiodini, I ;

Bianchi, D ;

Attard, M ;

Trischitta, V ;

Bruno, R ;

Giannasio, P ;

Pontecorvi, A ;

Filetti, S .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (06) :358-364

[5] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study [J].

Cohen, Ezra E. W. ;

Rosen, Lee S. ;

Vokes, Everett E. ;

Kies, Merrill S. ;

Forastiere, Arlene A. ;

Worden, Francis P. ;

Kane, Madeleine A. ;

Sherman, Eric ;

Kim, Sinil ;

Bycott, Paul ;

Tortorici, Michael ;

Shalinsky, David R. ;

Liau, Katherine F. ;

Cohen, Roger B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4708-4713

[6] Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].

Davies, L ;

Welch, HG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167

[7] A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma [J].

de Groot, J. W. B. ;

Zonnenberg, B. A. ;

van Ufford-Mannesse, P. Quarles ;

de Vries, M. M. ;

Links, T. P. ;

Lips, C. J. M. ;

Voest, E. E. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3466-3469

[8] RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors [J].

de Groot, Jan Willem B. ;

Links, Thera P. ;

Plukker, John T. M. ;

Lips, Cornelis J. M. ;

Hofstra, Robert M. W. .

ENDOCRINE REVIEWS, 2006, 27 (05) :535-560

[9] Phase II trial of sunitinib in medullary thyroid cancer (MTC) [J].

De Souza, J. A. ;

Busaidy, N. ;

Zimrin, A. ;

Seiwert, T. Y. ;

Villaflor, V. M. ;

Poluru, K. B. ;

Reddy, P. L. ;

Nam, J. ;

Vokes, E. E. ;

Cohen, E. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[10] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

← 1 2 3 4 5 →